Literature DB >> 15989967

MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription.

Xiaoting Zhang1, Andrew Krutchinsky, Aya Fukuda, Wei Chen, Soichiro Yamamura, Brian T Chait, Robert G Roeder.   

Abstract

Human TRAP/Mediator is a key coactivator for many transcription factors that act through direct interactions with distinct subunits, and MED1/TRAP220 is the main subunit target for various nuclear receptors. Remarkably, the current study shows that MED1/TRAP220 only exists in a TRAP/Mediator subpopulation (less then 20% of the total) that is greatly enriched in specific TRAP/Mediator subunits and is tightly associated with a near stoichiometeric level of RNA polymerase II. Importantly, this MED1/TRAP220-containing holoenzyme supports both basal- and activator-dependent transcription in an in vitro system lacking additional RNA polymerase II. Furthermore, chromatin immunoprecipitation experiments demonstrate an activator-selective recruitment of MED1/TRAP220-containing versus MED1/TRAP220-deficient TRAP/Mediator complexes to estrogen receptor (ER) and p53 target genes, respectively. Finally, RNAi studies show that MED1/TRAP220 is required for ER-mediated transcription and estrogen-dependent breast cancer cell growth. These observations have significant implications for our current understanding of the composition, heterogeneity, and functional specificity of TRAP/Mediator complexes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15989967     DOI: 10.1016/j.molcel.2005.05.015

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  70 in total

Review 1.  The human Mediator complex: a versatile, genome-wide regulator of transcription.

Authors:  Dylan J Taatjes
Journal:  Trends Biochem Sci       Date:  2010-03-17       Impact factor: 13.807

2.  A Mediator-responsive form of metazoan RNA polymerase II.

Authors:  Xiaopeng Hu; Sohail Malik; Costin Catalin Negroiu; Kyle Hubbard; Chidambaram Natesa Velalar; Brian Hampton; Dan Grosu; Jennifer Catalano; Robert G Roeder; Averell Gnatt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-12       Impact factor: 11.205

3.  Specific erythroid-lineage defect in mice conditionally deficient for Mediator subunit Med1.

Authors:  Melanie Stumpf; Xiaojing Yue; Sandra Schmitz; Hervé Luche; Janardan K Reddy; Tilman Borggrefe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-23       Impact factor: 11.205

4.  CDK8 is a stimulus-specific positive coregulator of p53 target genes.

Authors:  Aaron Joseph Donner; Stephanie Szostek; Jennifer Michelle Hoover; Joaquin Maximiliano Espinosa
Journal:  Mol Cell       Date:  2007-07-06       Impact factor: 17.970

5.  ETV4 and AP1 Transcription Factors Form Multivalent Interactions with three Sites on the MED25 Activator-Interacting Domain.

Authors:  Simon L Currie; Jedediah J Doane; Kathryn S Evans; Niraja Bhachech; Bethany J Madison; Desmond K W Lau; Lawrence P McIntosh; Jack J Skalicky; Kathleen A Clark; Barbara J Graves
Journal:  J Mol Biol       Date:  2017-07-17       Impact factor: 5.469

6.  ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification.

Authors:  June X Zou; Alexey S Revenko; Li B Li; Abigael T Gemo; Hong-Wu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-12       Impact factor: 11.205

Review 7.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

8.  RNA polymerase II C-terminal heptarepeat domain Ser-7 phosphorylation is established in a mediator-dependent fashion.

Authors:  Stefan Boeing; Caroline Rigault; Martin Heidemann; Dirk Eick; Michael Meisterernst
Journal:  J Biol Chem       Date:  2009-11-09       Impact factor: 5.157

9.  Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles.

Authors:  Yijuan Zhang; Marissa Leonard; Yi Shu; Yongguang Yang; Dan Shu; Peixuan Guo; Xiaoting Zhang
Journal:  ACS Nano       Date:  2016-12-16       Impact factor: 15.881

10.  ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Authors:  Feng Jin; Shazia Irshad; Wei Yu; Madesh Belakavadi; Marina Chekmareva; Michael M Ittmann; Cory Abate-Shen; Joseph D Fondell
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.